Protalix Sees Share Price Spike Amid Ebola Threat

October 19, 2014 | The Israeli biopharmaceutical company Protalix Biotherapeutics saw an 11 percent spike in its share price amid growing Ebola concerns in the United States. Protalix, which recently went public on the New York Stock Exchange, has developed a plant-based cell expression system that could potentially be used to produce the experimental ZMapp drug. Protalix’s share price similarly rose 20 percent after the inventor of Protalix’s technology, Prof. Yoseph Shaaltiel suggested that the company’s technology could be used to create the ZMapp treatment. Protalix specializes in the development of treatments from plant-based recombinant therapeutic proteins.